Nouvelle déclaration d'incident
No de la demande: 2020-2280
Numéro de référence du titulaire d'homologation: 2019-CA-000109
Nom du titulaire (nom légal complet, aucune abbréviation): The Hartz Mountain Corporation
Adresse: 400 Plaza Drive
Ville: Seacaucus
État: New Jersey
Pays: USA
Code postal /Zip: 07094-3688
Incident chez un animal domestique
Pays: CANADA
État: BRITISH COLUMBIA
ARLA No d'homologation 30735 ARLA No de la demande d'homologation EPA No d'homologation.
Nom du produit: Hartz UltraGuard Flea and Tick Drops for Dogs Over 28 kg
Oui
Inconnu
Site: Animal / Usage sur un animal domestique
Non
Propriétaire de l'animal
Dog / Chien
American Staffordshire Terrier Crossbred
1
Homme
4
45
lbs
Cutanée
>3 days <=1 wk / >3 jours <=1 sem
>24 hrs <=3 days / >24 h <=3 jours
Système
Unknown / Inconnu
Non
Non
Unknown/Inconnu
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On 24-Jul-2019, a 4 year old, 45 pound, neutered, male, American Staffordshire Terrier crossbred dog, in unknown condition, with concomitant medical conditions of allergies and fleas, was administered an overdose of 1 tube of Hartz UltraGuard Flea and Tick Drops for Dogs Over 28 kg (Phenothrin) via the topical route by the animal owner. This was an extra label use of the product. On 27-Jul-2019, the dog developed an application site lesion and application site hair loss. On 29-Jul-2019, the animal owner bathed the dog in liquid dish soap. The dog had not been evaluated by a veterinarian, no treatment had been performed and the clinical signs continued. Veterinary evaluation was recommended if the clinical signs persisted or worsened. No further information was received in this case.
Mineure
The information contained in this report is based on self-reported statements provided to the registrant during telephone Interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and can not form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.